Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Cash from Operations (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Cash from Operations for 7 consecutive years, with 17788000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 62.68% to 17788000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 128336000.0, a 17.47% increase, with the full-year FY2025 number at 128336000.0, up 17.47% from a year prior.
  • Cash from Operations was 17788000.0 for Q4 2025 at Pliant Therapeutics, up from 21081000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 13665000.0 in Q1 2021 to a low of 48864000.0 in Q1 2025.
  • A 5-year average of 28513700.0 and a median of 24930500.0 in 2023 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: plummeted 349.65% in 2021, then soared 62.68% in 2025.
  • Pliant Therapeutics' Cash from Operations stood at 19865000.0 in 2021, then plummeted by 57.26% to 31239000.0 in 2022, then increased by 19.65% to 25102000.0 in 2023, then plummeted by 89.87% to 47662000.0 in 2024, then skyrocketed by 62.68% to 17788000.0 in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Cash from Operations are 17788000.0 (Q4 2025), 21081000.0 (Q3 2025), and 40603000.0 (Q2 2025).